StockNews.AI
NBIX
StockNews.AI
204 days

Neurocrine Biosciences Announces Amendment to Strategic Collaboration with Takeda to Develop and Commercialize Osavampator (formerly NBI-1065845/TAK-653)

1. Neurocrine gains global rights for osavampator, boosting its MDD treatment portfolio. 2. Takeda retains rights in Japan, indicating market segmentation.

2m saved
Insight
Article

FAQ

Why Bullish?

Gaining exclusive worldwide rights may enhance revenue potential. Similar past agreements have positively affected stock prices.

How important is it?

The exclusive rights acquisition can lead to significant future cash flows. Previous exclusive deals have historically benefited companies like NBIX.

Why Long Term?

Long-term benefits expected as osavampator progresses through development stages. Historical data suggests gradual appreciation with successful drug development.

Related Companies

TKPHF
-       Neurocrine Obtains Exclusive Worldwide Development and Commercialization Rights Excluding Japan and Converts to Royalty-Bearing License for Osavampator -       Takeda Reacquires Rights to Osavampator in Japan SAN DIEGO , Jan. 27, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it has amended its agreement with Takeda to develop and commercialize osavampator (NBI-1065845/TAK-653). Under the amended agreement, Neurocrine will obtain exclusive rights for all indications to develop and commercialize osavampator, a potential first-in-class AMPA positive allosteric modulator in development for patients with inadequate response to treatment of major depressive disorder (MDD) in all territories worldwide except Japan, where Takeda will reacquire exclusive rights.

Related News